// App-Quantinova.ai

: Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma

Researchers

Presenter

  • Yanan Zheng

Principal Investigators

  • Ye Guan

  • Yuying Gao

  • Lu Liu

  • Lubna Abuqayyas

  • Åsa Hellqvist

  • Karin Bowen

  • Gene Colice

  • Alexander Macdonald

Medical Centers

  • Clinical Pharmacology Modelling and Simulation, Amgen, Cambridge, United States of America

  • Clinical and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, United States of America

  • Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, China

Locations

  • United States

  • China

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Tezepelumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved